All In Biotech

Drug Trial Radar · NCT03264989

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis

Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Dec 19, 2017

Primary completion

Jun 26, 2023

Study completion Jun 26, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the CSEG101A2202 study was to characterize the Pharmacokinetic (PK) and Pharmacodynamic (PD) of SEG101/crizanlizumab and to evaluate the safety and efficacy of SEG101/crizanlizumab in sickle cell disease (SCD) patients.

Conditions

  • Sickle Cell Disease (SCD)

Interventions

  • crizanlizumabDrug

    Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK): AUCd15 and AUCtau of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: 1st dose: Day 1: (pre-dose, 0.5, 1, 2, 4, 6 & 24 hours post dose, Days 4, 8 & 15; 5th dose: Day 1 (pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post dose), Days 4, 8, 15, 22 & 29
  2. PK: Cmax of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: After the starting dose (Week 1) and after multiple doses (steady state, Week 15)
  3. Pre-dose Concentrations Prior to Each Study Drug DoseTime frame: Pre-dose at Day 1 on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51
  4. Percentage of P-selectin Inhibition After the Starting Dose (PD-AUCd15), After Multiple Doses (PD-AUCd29) of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: 1st dose: Day 1: (pre-dose, 0.5, 1, 2, 4, 6 & 24 hours post dose, Days 4, 8, 15; 5th dose: Day 1(pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post dose), Days 4, 8, 15, 22 & 29
  5. Percentage of P-selectin Inhibition Prior to Each Study Drug Dose of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: Pre-dose on Day 1 for Weeks 3, 7, 11, 15, 19, 23, 27, 31,35, 39, 43, 47, 51 (at 0 hr or pre-dose)

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Orange, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Childrens Healthcare of Atlanta .

    Atlanta, Georgia

  • Augusta University Georgia Patient Treatment

    Augusta, Georgia

  • University of Maryland Medical Ctr

    Baltimore, Maryland

  • Childrens Hospital at Montefiore

    The Bronx, New York

  • Duke University Medical Center Patient Treatment

    Durham, North Carolina

  • East Carolina University East Carolina University

    Greenville, North Carolina

  • Childrens Hospital Of Philadelphia Patient Treatment

    Philadelphia, Pennsylvania

  • Medical Uni of South Carolina Medical Univ of SC

    Charleston, South Carolina

  • M Francisco Gonzalez MD PA .

    Columbia, South Carolina

  • Carolina Blood and Cancer Care of South Carolina

    Rock Hill, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.